1. Generics Bulletin
  2. >>Business
  3. >>Deals

Sandoz And Delpharm Renew Canadian Injectables Supply Agreement For 10 Years

French CDMO Planning Major Upgrades At Former Sandoz Canada Site In Boucherville

 
• By Dean Rudge

Along with financial backing from the Canadian government, a fresh, decade-long partnership with Sandoz Canada will allow Delpharm to carry out modernization plans for its manufacturing facility in Boucherville, securing the local supply chain for sterile injectable medicines.

Canada flag
• Source: Ferenz/Alamy Stock Photo (Ferenz / Alamy Stock Photo/Alamy Stock Photo)

Sandoz’s Canadian operation has inked a fresh ten-year supply agreement with French CDMO Delpharm Industrie, in a pact designed to secure a reliable supply of sterile injectables made in Canada. The deal is part of a larger scheme powering Delpharm’s planned upgrades to its manufacturing facility in Boucherville, Quebec, which currently produces 20 of the 100 critical medicines “vital to the Canadian healthcare system.”

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Hikma Secures US Rights To Novugen’s Generic Trametinib

 
• By Adam Zamecnik

The move adds another compound with the coveted 180-day exclusivity to Hikma’s portfolio for an undisclosed sum.

Xbrane Approves Deal Giving Away Cimzia Rival To Alvotech

 
• By Adam Zamecnik

After announcing the agreement last month, Xbrane has now approved its deal with Alvotech as part of an extra general meeting.

Polpharma Looks To Supercharge Biosimilar Development With Help Of Chime

 
• By Dean Rudge

With six biosimilars reportedly in development, Polpharma Biologics has linked up with Chinese CDMO Chime Biologics, looking to tap its “all-in-one solutions to accelerate biosimilar development and reduce the time-to-market” for an undisclosed biosimilar product.

Fresenius Divests Brazilian Sites To EMS Amid Structural Streamlining

 
• By Adam Zamecnik

The divestment marks a further step in Fresenius’ ongoing strategy towards a more optimized and simplified company structure while doubling down on new endeavors in the Biopharma space.

More from Manufacturing

Viatris Rocked By Indore US Block, With $500m Revenue Sting Anticipated In 2025

 
• By Dean Rudge

Viatris anticipates that half-a-billion dollars will disappear from its top line in 2025 on the back of the recent import alert for its oral solids facility in Indore, with much of the pain being caused by the firm’s failure to have its generic version of Revlimid exempt from the restrictions.

Adcock Bemoans Wadeville Plant Jam As Trading Profit Dives, Revenues Freeze

 
• By Dean Rudge

South Africa’s Adcock Ingram struck a downbeat tone during its financial first-half results call, as multiple factors conspired to produce a performance “well below expectations.”

Celltrion Offers Update On US Tariffs Strategy

 
• By Dave Wallace

In an update to its strategy for dealing with US tariffs, Korea’s Celltrion has revealed actions taken so far, as well as outlining plans to consider moving “swiftly” to secure US manufacturing for APIs if circumstances demand.